engage checkpoint medical linkedin twitter

Nursing Support for mCRPC Patients During Radiopharmaceutical Treatment

Nursing Support for mCRPC Patients During Radiopharmaceutical Treatment

A clinical update for oncology nurses

A clinical update for oncology nurses

Janet Forgenie

In this video update, Uro-oncology Clinical Nurse Specialist Janet Forgenie explains how nurses can support patients undergoing radiopharmaceutical treatment for metastatic castrate-resistant prostate cancer (mCRPC).

Watch the video and download the accompanying slides to learn about:

  • The considerations for treatment selection in clinical practice to minimise the impact on patients' lives
  • Applying recent data to treatment sequencing in bone-dominant mCRPC
  • Educating and supporting patients during treatment so they know what to expect
Image of Janet Forgenie
Janet Forgenie

Uro-Oncology Clinical Nurse Specialist

University College Hospital

United Kingdom (UK)

preview next

Nursing Support for mCRPC patients during radiopharmaceutical treatment

time Video | open 3 min | Jul 2023

This programme was made for you:   your opinion matters

Share your feedback in just 4 clicks and help us to continue to create the content you need.

I agree that this educational programme:

Clinical Takeaways

  • Radiopharmaceuticals such as radium-223 and 177Lu-PSMA-617 offer a survival benefit to mCRPC patients as well as managing bone pain and QOL

  • They are able to deliver targeted radiation to prostate cancer cells, thereby minimising toxicity to normal healthy tissue

  • Real-world data support using 177Lu-PSMA in patients who previously received Ra-223

  • Nurses and patients should be aware of post-treatment precautions, but radiopharmaceuticals are an effective and manageable treatment option for mCRPC patients


This programme is endorsed by

This educational programme is supported by an Independent Medical Education Grant from Bayer

GU NURSES CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.

Other programmes of interest